Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma

Inclusion Criteria:

* Histological documentation of esophageal squamous cell carcinoma;
* At least one measurable lesion (by RECIST1.1);
* Patients who have failed to a chemoradiation treatment;
* 18-75，ECOG PS:0-1,Life expectancy of more than 12 weeks;
* No treated with molecular targeted drugs;
* Main organs function is normal;
* Patients should participate in the study voluntarily and sign informed consent;

Exclusion Criteria:

* Allergic to anlotinib and/or its excipients;
* Patients with any severe and/or unable to control diseases，including：

  1. Blood pressure unable to be controlled ideally(systolic pressure \>140 mmHg，diastolic pressure\>90 mmHg);
  2. Patients with Grade 2 or higher myocardial ischemia, myocardial infarction or malignant arrhythmias(including QT≥450ms for male， QT≥470ms for female) and patients with Grade 3 or higher congestive heart failure (NYHA Classification) or LVEF\<50%;
* Patients with a clear Gastrointestinal bleeding tendency include the following situations: Local active ulcer lesions, and fecal occult blood (+ +) ; The patient had a history of black and hematemesis within 2 months;
* Patients with a bleeding tendency and INR\>1.5,APTT\>1.5 ULN ;
* Patients with factors that could affect oral medication (such as dysphagia，chronic diarrhea, intestinal obstruction etc.);
* Patients with active brain metastasis, cancerous meningitis, spinal cord compression patients or found in Screening stage;
* Patients treated with VEGFR inhibitor;
* Patients with drug abuse history and unable to get rid of or Patients with mental disorders;
* Patients participated in other anticancer drug clinical trials within 4 weeks;
* Patients with concomitant diseases which could seriously endanger their own safety or could affect completion of the study according to investigators' judgment;